Dabigatran Composition Using Surface-Modified Acidic Excipients
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Dabigatran etexilate mesylate has poor solubility in neutral and alkaline media, leading to low oral bioavailability, and existing formulations face issues with high production costs, complex processes, and drug loss due to the use of organic acids to enhance bioavailability.
Innovation Solution
A surface-modified acidic or alkaline medicinal auxiliary material is treated with an aqueous solution of an alkaline or acidic substance to form a neutral salt layer, improving solubility and stability while simplifying the production process.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If organic acid is added to improve solubility and bioavailability of dabigatran etexilate mesylate, then solubility and bioavailability are improved, but production cost increases and production process becomes complex
Solution Approach 1:
The patent applies preliminary action by pre-coating the acid core material with an insulating layer before adding the active substance. This preliminary coating prevents direct contact between the acid and dabigatran etexilate mesylate during storage and processing, eliminating the need for complex post-processing steps while maintaining the acid microenvironment needed for solubility and bioavailability enhancement.
Solution Approach 2:
The patent segments the formulation into distinct functional layers: an acid core material providing the acid microenvironment, an insulating layer preventing direct acid-drug interaction, and an active substance layer containing dabigatran etexilate mesylate. This segmentation allows each component to perform its function independently, simplifying the overall production process while maintaining efficacy.
2Reliability
If organic acid is used to create acid microenvironment for enhanced dissolution, then dissolution and absorption are improved, but drug stability deteriorates due to chemical degradation
Solution Approach 1:
The patent uses an insulating layer as an intermediary between the acid core material and the active substance. This intermediate layer allows the acid core to create the necessary acid microenvironment for dissolution while preventing direct harmful chemical interactions with dabigatran etexilate mesylate, thus maintaining both dissolution performance and drug stability.
Solution Approach 2:
The patent applies local quality by creating an acid microenvironment only in the core region where it is needed for dissolution, while the outer regions where the drug is located maintain neutral or stable conditions. This spatial differentiation of chemical environment ensures optimal dissolution without compromising drug stability.
3Stability of the object's composition
If multiple coating layers are applied to separate acid core from active substance, then drug stability is improved, but manufacturing precision requirements increase and production time increases
Solution Approach 1:
The patent merges the insulating function and the drug protection function into a single integrated insulating layer coating. This unified approach provides both physical separation and chemical protection in one coating step, reducing the number of precise coating operations needed while maintaining drug stability.
4Reliability
If acid core material is used to enhance bioavailability, then solubility is improved, but loss of substance increases due to drug degradation
Solution Approach 1:
The insulating layer acts as a protective intermediary that prevents direct contact between dabigatran etexilate mesylate and the acid core material. This eliminates chemical degradation pathways while preserving the acid-mediated dissolution mechanism, thereby improving bioavailability without increasing drug loss.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified pharmaceutical composition achieves high solubility, bioavailability, and improved storage stability with reduced production costs, suitable for drugs sensitive to acids or alkalis.
Implementation Method 1
A surface-modified acidic or alkaline medicinal auxiliary material is treated with an aqueous solution of an alkaline or acidic substance to form a neutral salt layer
Data Source
AI summary
The present invention provides an oral pharmaceutical composition and a usage thereof, comprising a pharmaceutically acceptable acidic medicinal auxiliary material whose surface is modified and dabigatran etexilate or pharmaceutically acceptable salts or aquo-complexes thereof. The present invention further provides a surface modification method for a medicinal auxiliary material.